eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive About the journal Abstracting and indexing Subscription Contact Instructions for authors
vol. 9
Review paper

Chemotherapy-induced peripheral neuropathy as a clinical problem

Anna I. Ciszewska, Marcin Janecki, Angelika Copija, Ewa Nowakowska-Zajdel

Medycyna Paliatywna 2017; 9(4): 204–209
Online publish date: 2018/03/08
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of oncological treatment, leading to a substantial decrease in the quality of life of patients with cancer. It is commonly responsible for reduced efficiency or even cessation of the treatment effect because the effective anticancer drug dose is reduced or discontinued.

Despite the fact that we know more and more about CIPN pathophysiological mechanisms, the predictive factors, prevention, and treatment options are still very limited. The pathomechanism, clinical symptoms, and potential treatment options based of differences between oncological drugs responsible for CIPN are presented in this review. The potential risk factors that may increase the likelihood of developing CIPN, such as genetic background, are also described. This has potential future impact on extracting the CIPN high-risk group of patients qualified to specific oncological treatment options.

chemotherapy-induced peripheral neuropathy, pathomechanism, duloxetine

de Walden-Gałuszko K, Ciałkowska-Rysz A. Medycyna Paliatywna. Wydawnictwo Lekarskie PZWL, Warszawa 2015.
Dobrogowski J, Zajączkowska R, Dutka J, Wordliczek J. Patofizjologia i klasyfikacja bólu. Pol Przegl Neurol 2011; 7: 20-30.
Malec-Milewska M, Krajnik M, Wordliczek J. Chory na nowotwór. Kompendium leczenia bólu. Medical Education, Warszawa 2013.
Żylicz Z, Krajnik M. Jak powstaje ból? Neurofizjologia bólu dla początkujących. Pol Med Paliat 2003; 2: 49-56.
Bilińska M, Usnarska-Zubkiewicz L, Moszyńska A. Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej. Współcz Onkol 2008; 12: 441-446.
Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 2016; 140: 176-183.
Banach M, Juranek J, Antczak J. Neuropatie polekowe. Fam Med Prim Care Rev 2015; 17: 284-288.
Common Terminology Criteria for Adverse Events (CTCAE) Version 4,0.N.I.o.H. U.S. Department of Health and Human Services, National Cancer Institute. Editor 2009.
Postma TJ, Aaronson NK, Heimans JJ i wsp.; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41: 1135-1139.
Kerckhove N, Pereira B, Pezet D, Balayssac D. Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint. Pain 2017; 158: 180-182.
Hershman DL, Lacchetti C, Dworkin RH i wsp.; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-1967.
Kerckhove N, Collin A, Condé S i wsp. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 2017; 8: 86.
Kim PY, Johnson CE. Chemotherapy-induced peripheral neuropathy: a review of recent findings. Curr Opin Anaesthesiol 2017; 30: 570-576.
Shinde SS, Seisler D, Soori G i wsp. Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. Support Care Cancer 2016; 24: 547-553.
Zimmerman C, Atherton PJ, Pachman D i wsp. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 2016; 24: 1071-1078.
Schloss JM, Colosimo M, Airey C i wsp. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer 2017; 25: 195-204.
Dzierżanowski T, Ciałkowska-Rysz A. Leki przeciwdrgawkowe w leczeniu adjuwantowym bólu nowotworowego. Med Paliat 2012; 4: 197-203.
van den Heuvel SAS, van der Wal SEI, Smedes LA i wsp. Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res Manag 2017; 2017: 8053474.
Wong R, Major P, Sagar S. Phase 2 study of acupuncture-like transcutaneous nerve stimulation for chemotherapy-induced peripheral neuropathy. Integr Cancer Ther 2016; 15: 153-164.
Pignata S, Scambia G, Katsaros D i wsp.; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15: 396-405.
Katsumata N, Yasuda M, Takahashi F i wsp.; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.
Pignata S, De Placido S, Biamonte R i wsp. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6: 5.
Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 2014; 22: 1999-2007.
Park SB, Lin CS, Krishnan AV i wsp. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16: 708-716.
Andre T, Boni C, Navarro M i wsp. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
Yothers G, O’Connell MJ, Allegra CJ i wsp. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774.
Banach M, Jurczyszyn A, Skotnicki A. [Thalidomide induced peripheral neuropathy in multiple myeloma patients]. Przegl Lek 2015; 72: 629-635.
Hertz DL, Roy S, Jack J i wsp. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 2014; 145: 245-254.
McLeod HL, Sargent DJ, Marsh S i wsp. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233.
Oldenburg J, Kraggerud SM, Brydoy M i wsp. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007; 5: 70.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe